Widespread and abundant α-synuclein pathology in a neurologically unimpaired subject

被引:59
作者
Parkkinen, L
Pirttilä, T
Tervahauta, M
Alafuzoff, I
机构
[1] Univ Kuopio, Dept Neurol & Neurosci, Sect Neuropathol, FIN-70211 Kuopio, Finland
[2] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland
[3] Kuopio Univ Hosp, Dept Pathol, SF-70210 Kuopio, Finland
[4] Leppavirta Hlth Care Ctr, Leppavirta, Finland
关键词
alpha-synuclein; beta-amyloid; gliosis; inclusion; neurologically unimpaired;
D O I
10.1111/j.1440-1789.2005.00644.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The intracytoplasmic aggregation of alpha-synuclein (alpha S) protein is a common denominator for a group of neurodegenerative disorders currently known as synucleinopathies. It is generally assumed that the incorporation of alpha S protein into compact inclusions compromises the function and viability of its host cell via mechanical disruption. Herein, we report a widespread and abundant alpha S pathology in an elderly subject, whose medical history gave no indication of any neurodegenerative disease. We compared neuronal and glial components in this neurologically unimpaired subject with a patient with a clinical syndrome of dementia with Lewy bodies (DLB) by using a range of antigenic determinants and an in situ end-labeling technique. We detected no differences in vascular pathologies, in gliosis, or in apoptosis that would have explained the incompatible clinical end-points. With respect to the Alzheimer's disease-related changes, the only differences noted were the beta-amyloid aggregates in the putamen found in the DLB patient alone. Our findings suggest that there must be some currently unidentified factors rather than alpha S-positive inclusions that are responsible for the neuronal dysfunction. The alpha S-positive inclusions may well represent detoxified reserves that cells can tolerate for years, and thus prevention of their development could actually accelerate the diseases process.
引用
收藏
页码:304 / 314
页数:11
相关论文
共 49 条
[1]  
ALAFUZOFF I, 1999, STROKE, V30, P613
[2]   Parkinson disease neuropathology - Later-developing dementia and loss of the levodopa response [J].
Apaydin, H ;
Ahlskog, JE ;
Parisi, JE ;
Boeve, BF ;
Dickson, DW .
ARCHIVES OF NEUROLOGY, 2002, 59 (01) :102-112
[3]   Chaperone suppression of α-synuclein toxicity in a Drosophila model for Parkinson's disease [J].
Auluck, PK ;
Chan, HYE ;
Trojanowski, JQ ;
Lee, VMY ;
Bonini, NM .
SCIENCE, 2002, 295 (5556) :865-868
[4]   Chronic systemic pesticide exposure reproduces features of Parkinson's disease [J].
Betarbet, R ;
Sherer, TB ;
MacKenzie, G ;
Garcia-Osuna, M ;
Panov, AV ;
Greenamyre, JT .
NATURE NEUROSCIENCE, 2000, 3 (12) :1301-1306
[5]   Staging of brain pathology related to sporadic Parkinson's disease [J].
Braak, H ;
Del Tredici, K ;
Rüb, U ;
de Vos, RAI ;
Steur, ENHJ ;
Braak, E .
NEUROBIOLOGY OF AGING, 2003, 24 (02) :197-211
[6]   NEUROPATHOLOGICAL STAGING OF ALZHEIMER-RELATED CHANGES [J].
BRAAK, H ;
BRAAK, E .
ACTA NEUROPATHOLOGICA, 1991, 82 (04) :239-259
[7]   Protofibrils, pores, fibrils, and neurodegeneration: Separating the responsible protein aggregates from the innocent bystanders [J].
Caughey, B ;
Lansbury, PT .
ANNUAL REVIEW OF NEUROSCIENCE, 2003, 26 :267-298
[8]   Lewy body cortical involvement may not always predict dementia in Parkinson's disease [J].
Colosimo, C ;
Hughes, AJ ;
Kilford, L ;
Lees, AJ .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (07) :852-856
[9]   Pathology and neurotransmitter abnormalities of dementia with Lewy bodies [J].
Duda, JE .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2004, 17 :3-14
[10]  
Esiri MM, 2001, LANCET, V357, P169